Found: 5
Select item for more details and to access through your institution.
Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm<sup>3</sup>: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial.
- Published in:
- PLoS ONE, 2014, v. 9, n. 12, p. 1, doi. 10.1371/journal.pone.0114602
- By:
- Publication type:
- Article
Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin.
- Published in:
- PLoS ONE, 2009, v. 4, n. 9, p. 1, doi. 10.1371/journal.pone.0006999
- By:
- Publication type:
- Article
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Availability and use of Standards in vaccine development.
- Published in:
- NPJ Vaccines, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41541-023-00692-0
- By:
- Publication type:
- Article
A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
- Published in:
- 2018
- By:
- Publication type:
- journal article